GET DAILY SIGNALSBlack Diamond Therapeutics (BDTX) Q3 2026 Earnings Preview: Focus on Cash Runway and Clinical Updates
Key Takeaways
- Black Diamond Therapeutics (BDTX) is set to report third-quarter 2026 results in early November for the period ended September 30, 2026.
- Wall Street consensus points to a net loss of about $0.06 per share, an improvement from the $0.15 per share loss in the year-ago quarter.
- The company has beaten consensus EPS estimates in eight straight quarters, based on MarketBeat data.
- As a clinical-stage biotech with no product revenue, attention will center on operating discipline, cash position, and runway rather than top-line sales.
- The lead candidate silevertinib continues to advance in Phase 2 for frontline non-small cell lung cancer, with fresh data expected as a key near-term catalyst.
Why This Earnings Report Matters
Black Diamond Therapeutics develops “MasterKey” therapies aimed at families of oncogenic mutations in cancer. With no meaningful product revenue, quarterly results serve mainly as a check on operating costs, balance-sheet health, and progress toward clinical goals. I pay particular attention to research-and-development spending and the cash runway, which shows how long the company can advance its trials before needing fresh capital. This report arrives just as management prepares updated Phase 2 data for silevertinib in newly diagnosed lung-cancer patients, so the release could influence sentiment around the stock.
Consensus Estimates and Track Record
Analysts project a net loss of roughly $0.06 per share for the third quarter of 2026, with consensus revenue near $8.33 million that largely reflects collaboration or licensing income. That compares with a $0.15 per share loss in the same quarter of 2025. BDTX has a solid history of topping expectations, including a second-quarter 2026 loss of $0.17 per share versus a $0.20 estimate. MarketBeat notes eight consecutive beats. Estimates do vary across providers, with some looking for losses between $0.03 and $0.10 per share. Given the pre-revenue profile, I expect investors to focus more on cash burn, cash balance, and any updates on the silevertinib program than on the headline EPS number itself. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Clinical Momentum and Sentiment Heading Into the Report
Investor focus remains on clinical catalysts rather than the financials. Recent quarters have shown narrow losses, highlighted by a second-quarter 2026 central-nervous-system objective response rate of 86 percent for silevertinib in frontline non-small cell lung cancer patients with non-classical EGFR mutations. That data has kept attention on the drug’s potential regulatory path. Risks include the timing and detail of upcoming disclosures, any rise in R&D outlays as trials expand, and possible future financing or partnership moves. Because the company is still pre-revenue, the stock tends to react more to shifts in cash-runway guidance or clinical timelines than to the quarterly loss figure.
What to Watch Going Forward
Management has indicated plans to seek FDA feedback on a registrational path for silevertinib in frontline EGFR-mutant non-small cell lung cancer, so updated Phase 2 results—including objective response rate and early duration-of-treatment metrics—will be closely watched. Cash position is another key item: the company reported $135.5 million in cash and investments as of September 30, 2025, with later updates pointing to roughly $110 million and runway into 2028. A longer runway supports flexibility to finish trials without immediate dilution. Partnership opportunities in non-small cell lung cancer and glioblastoma are also on the radar, as management has expressed interest in collaborations to advance silevertinib into later-stage development. Any commentary on partnering, enrollment, or spending trends is likely to matter more than the earnings number alone. Clinical-stage biotech outcomes remain uncertain, so these factors should be viewed in that context.
Using AI Tools for Biotech Research
When I’m reviewing clinical-stage names like BDTX, I often turn to Tickeron’s AI-powered tools to quickly surface comparable companies and technical patterns. The AI Screener lets me filter by industry, market cap, and performance metrics in one place, which helps build a focused watchlist without manual effort. It’s become a regular part of my process for spotting ideas that align with my own strategy.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BDTX in +8.57% Uptrend, rising for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BDTX advanced for three days, in 199 of 241 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where BDTX's RSI Oscillator exited the oversold zone, 28 of 34 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 82%.
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BDTX as a result. In 58 of 69 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for BDTX turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 39 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
BDTX moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BDTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
BDTX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BDTX entered a downward trend on October 19, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.037) is normal, around the industry mean (3.482). P/E Ratio (-2.313) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (2.360) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 76 (best 1 - 100 worst), indicating slightly worse than average price growth. BDTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BDTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biotechnology company that discovers and develops therapeutic agents to target unique oncogenic protein-isoforms.
Industry Biotechnology
Advertisement